Forslind K, Boonen A, Albertsson K, Hafström I, Svensson B
Department of Medicine, Section of Rheumatology, Helsingborg Hospital, Sweden.
Scand J Rheumatol. 2009 Nov-Dec;38(6):431-8. doi: 10.3109/03009740902939376.
The aim of this study was to evaluate whether loss of bone measured by digital X-ray radiogrammetry (DXR) of hands early in the course of rheumatoid arthritis (RA) may predict future radiographic joint damage after 1 and 2 years.
A total of 166 patients with early RA, who were part of the Better Anti-Rheumatic FarmacOTherapy (BARFOT) low-dose prednisolone study, were included. The patients had been randomized to treatment with 7.5 mg prednisolone daily or no prednisolone when they started with their first disease-modifying anti-rheumatic drug (DMARD) therapy. Radiographs of hands and feet were taken at baseline and after 1 and 2 years and assessed by the van der Heijde modified Sharp (vdH-S) score. Hand bone density (HBD) was measured on the same radiographs by DXR. Changes in HBD and hand bone loss (HBL) were calculated. HBL was defined as a change in DXR bone mineral density (DXR-BMD) during the first year by more than 0.0048 g/cm(2).
HBL was found in 64% of the patients. Patients with HBL had radiological progression significantly more often than patients without (80% vs. 57%, p=0.012). Patients not treated with prednisolone had HBL more often than patients with this treatment (83% vs. 44%, p=0.001). In multiple regression analyses, HBL and change in DXR-BMD during the first year proved to be independent predictors of radiological progression.
Loss of bone measured by DXR was found to be an independent predictor of radiological joint damage and may thus be an additional tool in the process of treatment decision in early RA.
本研究旨在评估类风湿关节炎(RA)病程早期通过手部数字X线摄影测量法(DXR)测得的骨质流失是否可预测1年和2年后未来的放射学关节损伤。
共有166例早期RA患者纳入了更好的抗风湿药物治疗(BARFOT)低剂量泼尼松龙研究。这些患者在开始使用第一种改善病情抗风湿药物(DMARD)治疗时被随机分为每日服用7.5mg泼尼松龙治疗组或不服用泼尼松龙组。在基线、1年和2年后拍摄手足X线片,并通过范德海伊德改良夏普(vdH-S)评分进行评估。通过DXR在相同的X线片上测量手部骨密度(HBD)。计算HBD和手部骨质流失(HBL)的变化。HBL定义为第一年期间DXR骨矿物质密度(DXR-BMD)变化超过0.0048g/cm²。
64%的患者存在HBL。有HBL的患者放射学进展明显比无HBL的患者更常见(80%对57%,p=0.012)。未接受泼尼松龙治疗的患者比接受该治疗的患者更常出现HBL(83%对44%,p=0.001)。在多元回归分析中,HBL和第一年期间DXR-BMD的变化被证明是放射学进展的独立预测因素。
通过DXR测得的骨质流失是放射学关节损伤的独立预测因素,因此可能是早期RA治疗决策过程中的一种额外工具。